Shots:

• Inovio and IVI collaborate with Seoul National University Hospital to begin P-I/II clinical study of INO-4800 in South Korea
• The P-II study will assess the safety- tolerability- and immunogenicity of the INO-4800 vaccine in 40 adults aged 19-50 yrs. and will expand to enroll an additional 120 people aged 19-64 yrs. the companies expect the trial to be initiate in 2020
• The companies plan to initiate the clinical study in Jun’2020. The study will follow the study conducted in the US- began in Apr’2020. Earlier- the two companies collaborated to conduct P-I/IIa trials for a MERS vaccine (INO-4700/GLS-5300) developed by Inovio and GeneOne- evaluated in a clinical trial and has achieved promising results

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Inovio